InnoCare Pharma (HKEX: 09969; SSE: 688428), a pioneering biopharmaceutical company dedicated to the treatment of cancer and autoimmune diseases, is proud to announce that the first patient has been administered ICP-248, the Company’s innovative B-cell lymphoma-2 (BCL2) inhibitor, in a clinical trial taking place in China. This marks an exciting milestone in the development of this cutting-edge therapy.
ICP-248 is a revolutionary, orally-administered BCL2 inhibitor, designed to combat the most common forms of hematological malignancies, such as Non-Hodgkin’s lymphoma and acute lymphoblastic leukemia. This innovative drug can be utilized as monotherapy, or in combination with other treatments, including BTK inhibitors, to provide the most effective results.
ICP-248 is an exciting new anti-tumor therapy that works by targeting an important protein involved in cell death, BCL2. By selectively inhibiting BCL2 and restoring the process of programmed cell death, ICP-248 holds promise in treating a variety of hematologic malignancies caused by abnormal BCL2 expression.
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, proudly announced the development of ICP-248, a powerful asset in the field of hematology that has an anti-tumor effect for treating various hematologic malignancies. By combining ICP-248 with other InnoCare hematology products, an even greater synergistic effect can be achieved. The company’s innovative drugs also cover a variety of important hema-oncology targets, including the BTK inhibitor orelabrutinib, CD19 monoclonal antibody tafasitamab, novel targeted protein degrader ICP-490 and CD20xCD3 bispecific antibody ICP-B02. With these new treatment options, InnoCare is committed to providing hope and relief to more patients with hematologic tumors.
At InnoCare, we are dedicated to delivering innovative and effective treatments for cancer and autoimmune diseases that make a real difference in people’s lives. We specialize in liquid cancer, solid tumors and autoimmune diseases, for which there are currently significant unmet medical needs both in China and around the world. Our ambitious goal is to become a leader in the development and commercialization of first-in-class and/or best-in-class drugs to improve the lives of those affected. Our presence spans Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States, making us a truly global force in biopharmaceuticals.